Share on StockTwits

GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating restated by equities researchers at Beaufort Securities in a research report issued on Monday.

GSK has been the subject of a number of other recent research reports. Analysts at Shore Capital reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday. Separately, analysts at Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, July 29th. They now have a GBX 1,500 ($25.24) price target on the stock. Finally, analysts at Berenberg Bank cut their price target on shares of GlaxoSmithKline plc from GBX 1,740 ($29.28) to GBX 1,520 ($25.58) in a research note on Tuesday, July 29th. They now have a “hold” rating on the stock. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company. GlaxoSmithKline plc presently has a consensus rating of “Hold” and a consensus target price of GBX 1,656.86 ($27.88).

Shares of GlaxoSmithKline plc (LON:GSK) traded up 1.31% on Monday, hitting GBX 1435.00. 5,635,392 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of GBX 1200.668 and a one year high of GBX 1733.00. The stock has a 50-day moving average of GBX 1541. and a 200-day moving average of GBX 1601.93. The company’s market cap is £68.937 billion.

The company also recently announced a dividend, which is scheduled for Thursday, October 2nd. Investors of record on Wednesday, August 6th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.28%. The ex-dividend date is Wednesday, August 6th.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.